TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX)

Historical Holders from Q3 2021 to Q4 2025

Type / Class
Equity / Voting Common Stock, par value $0.0001 per share
Symbol
TCRX on Nasdaq
Shares outstanding
52,382,313
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
34,601,160
Total reported value
$62,910,264
% of total 13F portfolios
0%
Share change
-1,129,874
Value change
-$1,894,620
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
72
Price from insider filings
$0.8989
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Lynx1 Capital Management LP 15% +37% $14,143,225 +$4,500,000 7,857,347 +47% Lynx1 Capital Management LP 30 Jun 2025
BIOTECHNOLOGY VALUE FUND L P 10% $6,684,697 5,263,541 BVF PARTNERS L P/IL 31 Mar 2025
K2 HealthVentures Equity Trust LLC 6.9% $4,575,429 3,602,700 K2 HealthVentures Equity Trust LLC 31 Dec 2024
ADAGE CAPITAL PARTNERS GP, L.L.C. 7.1% $4,445,000 3,500,000 Adage Capital Management, L.P. 31 Dec 2024
Adage Capital Management, L.P. 2.5% $1,957,500 1,350,000 Adage Capital Management, L.P. 30 Jun 2025
BlackRock, Inc. 1.8% -72% $1,274,636 -$2,483,708 958,373 -66% BlackRock, Inc. 30 Jun 2025
EcoR1 Capital, LLC 1.3% $841,798 662,833 EcoR1 Capital, LLC 31 Mar 2025
As of 30 Sep 2025, TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) has 72 institutional shareholders filing 13F forms. They hold 34,601,160 shares. of 52,382,313 outstanding shares (66%) .

Top 25 institutional shareholders own 63% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
Lynx1 Capital Management LP 15% 7,857,347 0% 2.9% $14,300,372
BVF INC/IL 10% 5,226,074 0% 0.39% $9,511,455
BAKER BROS. ADVISORS LP 5.3% 2,784,792 0% 0.04% $5,068,321
BlackRock, Inc. 4.5% 2,382,764 -7.2% 0% $4,336,629
VANGUARD GROUP INC 4.4% 2,317,916 +7.8% 0% $4,218,607
Propel Bio Management, LLC 3.7% 1,932,304 -7.4% 3.5% $3,516,793
Aberdeen Group plc 2.6% 1,354,820 +52% 0% $2,465,772
Deer Management Co. LLC 2.4% 1,245,504 0% 0.2% $2,266,817
Alphabet Inc. 2.1% 1,077,080 0% 0.08% $1,960,286
Simplify Asset Management Inc. 1.7% 904,972 -14% 0.03% $1,647,049
MORGAN STANLEY 1.6% 847,537 -0.68% 0% $1,542,518
RENAISSANCE TECHNOLOGIES LLC 1.6% 829,919 +4.8% 0% $1,510,453
DC Funds, LP 1.2% 630,000 0% 37% $1,146,600
TANG CAPITAL MANAGEMENT LLC 1.1% 600,000 0% 0.04% $1,092,000
GEODE CAPITAL MANAGEMENT, LLC 1.1% 567,657 +0.23% 0% $1,033,532
MILLENNIUM MANAGEMENT LLC 0.89% 466,086 -26% 0% $848,277
TWO SIGMA INVESTMENTS, LP 0.8% 419,404 +15% 0% $763,315
CITADEL ADVISORS LLC 0.75% 390,747 +78% 0% $711,160
TWO SIGMA ADVISERS, LP 0.55% 288,800 +35% 0% $525,616
JPMORGAN CHASE & CO 0.45% 237,750 -17% 0% $432,705
BANK OF AMERICA CORP /DE/ 0.43% 223,024 +2.3% 0% $405,903
STATE STREET CORP 0.38% 197,313 -1.6% 0% $359,110
BROWN BROTHERS HARRIMAN & CO 0.27% 143,051 0% 0% $260,353
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.27% 140,400 -8.7% 0.01% $255,528
GOLDMAN SACHS GROUP INC 0.25% 130,980 -70% 0% $238,383

Institutional Holders of TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 0 $0 -$17 0
2025 Q3 34,601,160 $62,910,264 -$1,894,620 182% 72
2025 Q2 35,724,879 $51,820,655 -$5,881,536 145% 79
2025 Q1 40,135,840 $55,390,189 -$2,855,485 138% 92
2024 Q4 41,512,999 $126,202,372 -$5,946,742 304% 87
2024 Q3 41,835,445 $208,343,784 +$255,932 498% 86
2024 Q2 41,438,662 $242,462,174 +$40,505,809 585% 78
2024 Q1 34,291,369 $272,339,183 +$19,165,614 794% 65
2023 Q4 31,912,819 $186,051,442 +$7,357,775 583% 54
2023 Q3 28,588,231 $73,195,868 +$2,177,864 256% 32
2023 Q2 27,951,619 $69,879,871 +$45,817,227 250% 28
2023 Q1 9,651,730 $20,268,564 +$609,616 210% 27
2022 Q4 9,519,305 $14,788,379 -$121,392 155% 28
2022 Q3 9,508,092 $29,003,732 -$530,732 305.02% 24
2022 Q2 9,682,082 $30,449,817 +$1,526,723 314.49% 23
2022 Q1 9,368,530 $26,232,000 -$1,531,305 280% 23
2021 Q4 9,861,945 $44,380,000 -$2,457,430 450.01% 28
2021 Q3 10,134,939 $83,484,000 +$83,484,012 833.94% 26